Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62


Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database.

Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL.

Head Neck. 2018 May 13. doi: 10.1002/hed.24984. [Epub ahead of print]


Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Bhatia AK, Burtness BA, Decker RH.

J Clin Oncol. 2018 May 1;36(13):1269-1271. doi: 10.1200/JCO.2018.77.7987. Epub 2018 Mar 16. No abstract available.


NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.



Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2018 Apr 1;110(4):433-434. doi: 10.1093/jnci/djx230. No abstract available.


Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ.

Cancer. 2017 Dec 1;123(23):4653-4662. doi: 10.1002/cncr.30920. Epub 2017 Aug 7.


Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification.

Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ.

Ear Nose Throat J. 2017 Jul;96(7):E12-E18.


Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx042.


The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.

Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e317-e321. doi: 10.1016/j.prro.2017.02.004. Epub 2017 Feb 16.


The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA.

Cancer. 2017 Jul 15;123(14):2762-2772. doi: 10.1002/cncr.30598. Epub 2017 Mar 21.


Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study.

Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z.

JAMA Oncol. 2017 Aug 1;3(8):1107-1111. doi: 10.1001/jamaoncol.2016.5769.


Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.


Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.

Baxi SS, Dunn LA, Burtness BA.

Oral Oncol. 2016 Nov;62:147-148. doi: 10.1016/j.oraloncology.2016.10.007. Epub 2016 Oct 21. No abstract available.


A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.

Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA.

JAMA Oncol. 2017 Mar 1;3(3):358-365. doi: 10.1001/jamaoncol.2016.4581.


EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Oct;15(10):2486-2497. Epub 2016 Aug 9.


Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.

Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL.

Cancer. 2016 Dec 1;122(23):3624-3631. doi: 10.1002/cncr.30227. Epub 2016 Aug 1.


CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.


Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base.

Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL.

Cancer. 2016 Jun 15;122(12):1853-60. doi: 10.1002/cncr.29962. Epub 2016 Mar 28.


Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA.

Am J Clin Oncol. 2017 Aug;40(4):393-398. doi: 10.1097/COC.0000000000000171.


Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Husain ZA, Burtness BA, Decker RH.

J Clin Oncol. 2016 Feb 10;34(5):396-8. doi: 10.1200/JCO.2015.64.7586. Epub 2015 Dec 7. No abstract available.


Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.

Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE.

Ann Thorac Surg. 2015 Jan;99(1):270-6. doi: 10.1016/j.athoracsur.2014.08.033. Epub 2014 Nov 18.


Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.

Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA.

Clin Cancer Res. 2014 Oct 1;20(19):5041-51. doi: 10.1158/1078-0432.CCR-14-0051. Epub 2014 Aug 8.


Trends and variations in the use of adjuvant therapy for patients with head and neck cancer.

Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL.

Cancer. 2014 Nov 1;120(21):3353-60. doi: 10.1002/cncr.28870. Epub 2014 Jul 15.


Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).

Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA.

Ann Oncol. 2014 Oct;25(10):2036-41. doi: 10.1093/annonc/mdu248. Epub 2014 Jul 9.


Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA.

Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3.


Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):917-23. Erratum in: J Natl Compr Canc Netw. 2013 Dec 1;11(12):1458.


Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer.

Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein-Szanto AJ.

Head Neck. 2014 Aug;36(8):1113-9. doi: 10.1002/hed.23421. Epub 2013 Oct 26.


Multi-modality therapy for cancer of the esophagus and GE junction.

Tejani MA, Burtness BA.

Curr Treat Options Oncol. 2012 Sep;13(3):390-402. doi: 10.1007/s11864-012-0193-5. Review.


Informational Needs of Head and Neck Cancer Patients.

Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA.

Health Technol (Berl). 2012 Apr 1;2(1):57-62. Epub 2012 Feb 14.


Psychological functioning of caregivers for head and neck cancer patients.

Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY.

Oral Oncol. 2012 Jan;48(1):18-25. doi: 10.1016/j.oraloncology.2011.11.012. Epub 2011 Dec 9. Review.


Head and neck cancers.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F; National Comprehensive Concer Network.

J Natl Compr Canc Netw. 2011 Jun 1;9(6):596-650. Review. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Jul;9(7):xxxiii.


Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ.

Am J Clin Oncol. 2011 Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a.


Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19.


Advanced gastric cancer: new treatments raise new questions.

Burtness BA.

Gastrointest Cancer Res. 2008 May;2(3):158-9. No abstract available.


Targeting EGFR resistance networks in head and neck cancer.

Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS.

Cell Signal. 2009 Aug;21(8):1255-68. doi: 10.1016/j.cellsig.2009.02.021. Epub 2009 Mar 1. Review.


The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Mehra R, Cohen RB, Burtness BA.

Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50. Review.


Head and neck cancers.

National Comprehensive Cancer Network, Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL Jr, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F.

J Natl Compr Canc Netw. 2008 Aug;6(7):646-95. No abstract available.


A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.

Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group.

Ann Oncol. 2008 May;19(5):977-83. doi: 10.1093/annonc/mdm591. Epub 2008 Feb 21.


Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.

Forastiere AA, Burtness BA.

J Clin Oncol. 2007 Jun 1;25(16):2152-5. No abstract available.


Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.

Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG.

Cancer Invest. 2007 Feb;25(1):19-26.


Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.

Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA.

Breast Cancer Res Treat. 2007 Sep;104(3):341-9. Epub 2006 Oct 19.


Novel targets in pancreatic cancer: focus on future paths to therapy.

Cohen SJ, Burtness BA.

Expert Opin Ther Targets. 2006 Oct;10(5):771-5.


Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.

Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA.

Cancer J. 2006 May-Jun;12(3):212-21.


Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray.

Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA.

Cancer. 2006 Apr 15;106(8):1677-84.


Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.

Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA.

Invest New Drugs. 2006 Mar;24(2):135-40.


Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.

Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA.

Oncology. 2005;69(5):372-83. Epub 2005 Nov 24.


Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.

Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA.

Clin Cancer Res. 2005 Aug 15;11(16):5856-62.


Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.

Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL.

J Clin Oncol. 2004 Aug 1;22(15):3061-9.


Surgical treatment of esophageal cancer.

Knisely JP, Burtness BA, Salem RR.

N Engl J Med. 2003 Mar 20;348(12):1177-9; author reply 1177-9. No abstract available.


Phase I study of perillyl alcohol in patients with refractory malignancies.

Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A.

Cancer Biol Ther. 2002 Mar-Apr;1(2):130-5.


Supplemental Content

Loading ...
Support Center